Dashboard
Manage Tickers

ACRS Aclaris Therapeutics, Inc.

Nasdaq aclaristx.com


$ 2.30 $ 0.17 (7.98 %)    

Tuesday, 11-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 2.3
$ 2.10
$ 2.14 x 200
$ 2.60 x 500
$ 2.10 - $ 2.34
$ 1.05 - $ 5.17
971,184
na
249.19M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-07-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-03-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 03-12-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-23-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aclaris-therapeutics-q3-eps-012-beats-014-estimate-sales-3299m-beat-1405m-estimate
Aclaris Therapeutics Q3 EPS $(0.12) Beats ...
11/06/2025 12:24:58

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of ...

hc-wainwright--co-reiterates-buy-on-aclaris-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Acla...
10/20/2025 11:39:29

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $1...

aclaris-therapeutics-to-host-2025-rd-day-in-midtown-new-york-on-october-14-to-discuss-its-progress-in-addressing-therapeutic-gaps-in-immuno-inflammatory-markets
Aclaris Therapeutics To Host 2025 R&D Day ...
09/30/2025 11:14:19

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candid...

aclaris-therapeutics-ati-2138-phase-2a-trial-results-to-be-presented-at-2025-eadv-congress-in-paris-for-moderate-to-severe-atopic-dermatitis
Aclaris Therapeutics' ATI-2138 Phase 2a Tr...
09/09/2025 11:20:22

- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis-WAYNE, Pa...

aclaris-therapeutics-q2-eps-013-beats-014-estimate-sales-1777m-beat-1435m-estimate
Aclaris Therapeutics Q2 EPS $(0.13) Beats ...
08/07/2025 11:19:56

stock-market-today-us-future-edge-higher-ahead-of-fomc-decisionmeta-microsoft-earnings-in-focus
Stock Market Today: US Future Edge Higher ...
07/30/2025 09:53:40

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher.

aclaris-therapeutics-stock-spikes-in-afterhours-session-following-major-announcement
Aclaris Therapeutics Stock Spikes In After...
07/30/2025 07:07:33

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 21:06:19

aclaris-therapeutics-reveals-top-line-results-from-open-label-phase-2a-trial-of-ati-2138--primary-endpoint-analysis-confirms-favorable-tolerability-profile-of-ati-2138-without-certain-risks-associated-with-other-agents-in-the-class-efficacy-results-show-comparable-outcomes-to-approved-therapies-with-potential-for-improved-tolerability-supporting-exploration-of-higher-doses-in-future-clinical-trials
Aclaris Therapeutics Reveals Top-Line Resu...
07/29/2025 20:04:25

WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical comp...

piper-sandler-assumes-aclaris-therapeutics-at-overweight-announces-price-target-of-6
Piper Sandler Assumes Aclaris Therapeutics...
07/10/2025 13:16:01

Piper Sandler analyst Biren Amin assumes Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight rating and announces Price Tar...

aclaris-therapeutics-added-to-russell-3000-and-russell-2000-indexes
Aclaris Therapeutics Added To Russell 3000...
06/30/2025 13:32:58

hc-wainwright--co-reiterates-buy-on-aclaris-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Acla...
06/25/2025 10:38:27

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $1...

aclaris-therapeutics-initiates-phase-1a1b-program-for-ati-052-the-companys-investigational-bispecific-anti-tslpil-4r-antibody-the-program-will-consist-of-a-phase-1a-single-and-multiple-ascending-dose-portion-in-healthy-volunteers-followed-by-an-expected-phase-1b-proof-of-concept-portion
Aclaris Therapeutics Initiates Phase 1a/1b...
06/23/2025 11:02:53

aclaris-therapeutics-has-initiated-a-randomized-double-blind-placebo-controlled-phase-2-trial-of-bosakitug-ati-045-for-moderate-to-severe-atopic-dermatitis-top-line-results-expected-in-the-second-half-of-2026
Aclaris Therapeutics Has Initiated A Rando...
06/02/2025 11:02:40

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/28/2025 12:08:42

this-arista-networks-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Arista Networks Analyst Begins Covera...
05/28/2025 11:43:44

wedbush-initiates-coverage-on-aclaris-therapeutics-with-outperform-rating-announces-price-target-of-8
Wedbush Initiates Coverage On Aclaris Ther...
05/28/2025 11:30:34

Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces ...

hc-wainwright--co-maintains-buy-on-aclaris-therapeutics-lowers-price-target-to-16
HC Wainwright & Co. Maintains Buy on Aclar...
05/14/2025 17:10:30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the pr...

aclaris-therapeutics-q1-eps-012-inline-sales-146m-beat-128m-estimate
Aclaris Therapeutics Q1 EPS $(0.12), Inlin...
05/08/2025 10:55:10

aclaris-therapeutics-fda-clears-ind-application-for-phase-1a1b-clinical-trial-of-ati-052-bispecific-anti-tslpil-4r-monoclonal-antibody-co-expects-to-initiate-trial-in-q2
Aclaris Therapeutics: FDA Clears IND Appli...
04/22/2025 11:02:31

- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -WAYNE, Pa, April 22, 2025 (GLOBE NE...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION